Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes
Launched by IANTREK, INC. · Aug 16, 2022
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a multicenter, observational registry of eligible adults with open angle glaucoma (OAG) in whom IOP-lowering surgery with the CycloPen Micro-Interventional System was performed are consecutively enrolled.
Data will be collected from the preoperative visit(s) that directly preceded surgery, the surgical procedure, and postoperative visits through 24 months after CycloPen System use.
Specific data to be collected includes details of the CycloPen surgical procedure, IOP, use of ocular hypotensive medications, and any side effects related to the surgery.
Gender
ALL
Eligibility criteria
- To be included, participants must have:
- • 1. Open angle glaucoma
- • 2. IOP-lowering surgical procedure using the CycloPen System
- • There are no exclusionary criteria.
About Iantrek, Inc.
iantrek, inc. is a pioneering biopharmaceutical company dedicated to advancing innovative therapeutic solutions for complex medical conditions. With a strong focus on research and development, iantrek leverages cutting-edge technology and a robust pipeline to address unmet clinical needs, particularly in areas such as oncology and autoimmune disorders. Committed to enhancing patient outcomes, the company collaborates with leading healthcare professionals and institutions to conduct rigorous clinical trials, ensuring the safety and efficacy of its products. Through its dedication to scientific excellence and ethical standards, iantrek, inc. aims to transform the landscape of modern medicine and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cape Coral, Florida, United States
Fort Myers, Florida, United States
Fort Washington, Pennsylvania, United States
Crossville, Tennessee, United States
Kenosha, Wisconsin, United States
Newport Beach, California, United States
Fort Myers, Florida, United States
Atlanta, Georgia, United States
Deland, Florida, United States
Salt Lake City, Utah, United States
Chevy Chase, Maryland, United States
Rockville, Maryland, United States
Las Vegas, Nevada, United States
New Brunswick, New Jersey, United States
New York, New York, United States
Fort Worth, Texas, United States
Ciudad De Panamá, , Panama
Patients applied
Trial Officials
Gautam Kamthan, MD
Study Director
Iantrek, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials